STOCK TITAN

Turn Therapeutics (TTRX) SEC Filings

TTRX NASDAQ

This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on dermatology, advanced wound care, infectious disease therapies, and intranasal vaccine initiatives. While no specific filings are listed in the provided data, Turn’s public communications reference its status as a Nasdaq-listed company and describe a direct listing structure used to enter the public markets.

For a company like Turn Therapeutics, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed information on clinical programs such as GX-03 for moderate to severe atopic dermatitis, late-stage efforts in onychomycosis, and vaccine initiatives based on its PermaFusion delivery platform. These reports often include discussions of research and development spending, risk factors related to clinical trials and regulatory pathways, and descriptions of commercial agreements, such as the global supply, development, and license agreement with Medline.

Other important SEC documents for a Nasdaq-listed biotechnology company can include current reports on Form 8-K, which may disclose material events like new strategic partnerships, changes to the Board of Directors, or significant financing arrangements. Filings related to equity financing structures, such as the GEM Global Yield agreement and share purchase agreements referenced in company updates, are also commonly detailed in SEC submissions.

On Stock Titan, Turn Therapeutics filings are supplemented with AI-powered summaries designed to explain key sections of lengthy documents in clear language. These tools can help users quickly understand complex topics such as clinical development disclosures, collaboration terms, and capital strategy without reading every page. As new TTRX filings are made available through EDGAR, this page can serve as a starting point for reviewing the company’s regulatory and financial reporting history.

EFFECT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
EFFECT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Turn Therapeutics Inc. may offer and sell common stock with an aggregate offering price of up to $50,000,000 from time to time through TD Cowen as sales agent or principal, including in at-the-market transactions. Net proceeds, if any, are intended for general corporate purposes, including research and development, preclinical and clinical development, working capital and capital expenditures. TD Cowen may receive up to 3.0% of gross proceeds from each sale.

The company had 30,532,704 shares outstanding as of September 30, 2026. Its dilution illustration assumes a $50,000,000 sale at $9.48 per share and estimates immediate dilution of $8.13 per share for purchasers; $9.48 was the November 6, 2026 closing price, and actual sales prices and share counts may vary.

GX-03, the lead investigational topical candidate for atopic dermatitis, completed Phase 2a in June 2026, with 50 subjects completing and 53 randomized. Week 4 vIGA-AD success was 59.3% for GX-03 (n=27) versus 30.4% for vehicle (n=23); no serious adverse events or treatment-related discontinuations occurred. Phase 2b is planned for 120–136 patients, with topline results expected in the first quarter of 2027; a Phase 2a study for hidradenitis suppurativa is also planned for that quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
prospectus
Rhea-AI Summary

Turn Therapeutics Inc. (TTRX) registered for resale by selling stockholders up to 25,362,950 shares of common stock, including up to 6,621,190 shares offered by GEM. Turn is not selling shares in this resale and receives none of its proceeds; the selling stockholders receive resale proceeds. GEM's portion includes 5,023,231 shares that may be issued through drawdowns and are registered for resale.

Separately, under the GEM Purchase Agreement, Turn may sell shares to GEM at its discretion through drawdown notices, subject to specified conditions, for up to $85.0 million in aggregate gross proceeds after the prospectus date. Turn estimates up to $84.95 million net over approximately 36 months if it sells shares for the full gross amount; it intends to use proceeds for working capital and general corporate purposes. The registered resale represents approximately 82.96% of the 30,572,704 common shares outstanding as of November 6, 2026. Turn warns that sales, or expectations of sales, could significantly reduce its share price.

The ongoing Phase 2b atopic dermatitis study is intended to enroll 120–136 patients, with topline results expected in the first quarter of 2027. In Phase 2a, 50 subjects completed the trial, with no serious adverse events or treatment-related discontinuations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
prospectus
-
Rhea-AI Summary

Turn Therapeutics Inc. furnished an updated investor presentation describing GX-03 development for atopic dermatitis (AD), onychomycosis and hidradenitis suppurativa (HS). For the ongoing AD Phase 2, the company reports Stage 1 intent-to-treat results from 50 participants: week-4 vIGA-AD success was 59.3% with GX-03 versus 30.4% with vehicle, and week-4 EASI-75 responses were 70.4% versus 52.2%. AD topline results are expected in Q1 2027; Phase 3 initiation is planned for mid-2027, subject to successful completion of each phase and capital availability.

The company reports approximately 70% complete cure with once-daily GX-03 and approximately 85% with twice-daily use in an approximately 100-participant onychomycosis study; Phase 3 initiation is planned for Q2 2027, subject to successful completion of each phase and capital availability. An HS Phase 2a trial's first patient dosing is planned for Q1 2027, subject to finalization. The company lists cash runway into Q3 2027 and current public-company G&A burn of approximately $1 million per quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
current report
-
Rhea-AI Summary

Turn Therapeutics Inc. may offer and sell, from time to time after the registration statement becomes effective, securities with an aggregate initial offering price of up to $150,000,000 under a shelf prospectus; each offering’s terms will be set in a prospectus supplement. Up to $50,000,000 of common stock under its sales agreement with TD Cowen is included in, not additional to, the shelf amount. Net proceeds are intended for general corporate purposes, including research and development, preclinical and clinical development, acquisitions or in-licensing, debt repayment, working capital and capital expenditures, unless a supplement specifies otherwise.

The company’s lead candidate, GX-03, is in a staged Phase 2 trial for atopic dermatitis. Phase 2a had 50 subjects complete the study; Phase 2b is planned to enroll 120-136 patients, with topline results expected in the first quarter of 2027. Turn plans to initiate a Phase 2a study of GX-03 for hidradenitis suppurativa in the first quarter of 2027. Common shares outstanding totaled 30,572,704 as of November 6, 2026, and the stock closed at $9.48 per share that day.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.27%
Tags
registration
Rhea-AI Summary

Turn Therapeutics Inc. (TTRX) registers for resale up to 25,362,950 shares of common stock by selling stockholders, including up to 6,621,190 shares by GEM. Of the total, 873,000 shares are being registered for the first time; other shares were originally registered under prior registration statements. The resale amount equals approximately 82.96% of the 30,572,704 common shares outstanding as of November 6, 2026.

The company will receive no proceeds from stockholder resales. Separately, it may sell shares to GEM under the GEM Purchase Agreement for up to $85.0 million in aggregate gross proceeds after the prospectus date, using draw-down notices; intended uses are working capital and general corporate purposes. GEM's purchase price is 90% of the average daily closing price during the applicable 15 consecutive trading days, with a $1.00-per-share floor. A requested draw-down cannot exceed 300% of average daily trading volume during the preceding 15 trading days. The prospectus estimates up to $84.95 million in net proceeds over approximately 36 months, assuming $85.0 million in aggregate gross proceeds. Of GEM's shares, 5,023,231 issuable under draw-down notices are registered for resale here; additional shares sold to GEM would first require an effective registration statement or amendment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.27%
Tags
registration
-
Rhea-AI Summary

Turn Therapeutics Inc. (TTRX) reported a $6,230,868 net loss for the three months ended September 30, 2026, versus $1,904,184 a year earlier; nine-month net loss was $13,051,733 versus $3,473,150. It reported no revenue for the nine-month periods. Nine-month research and development expense was $1,189,697, compared with $230,636.

Cash and cash equivalents were $10,363,975 at September 30, 2026, and operating activities used $4,105,574 during the first nine months. The company estimates this cash can fund GX-03 development in atopic dermatitis and hidradenitis suppurativa into the third quarter of 2027, but says capital may not fund operations through at least the next 12 months, raising substantial doubt about its ability to continue as a going concern.

Phase 2b of GX-03’s atopic dermatitis study is enrolling 120-136 patients, with topline results expected in the first quarter of 2027; Phase 2a, with 50 patients, was completed in June 2026. In a subsequent event, the company issued a 15-trading-day draw-down notice on October 29, 2026, putting 272,642 shares to the investor at a $10.00 threshold price for a $2.7 million advance; the final amount and share count will be determined at the end of the draw-down period.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.27%
Tags
quarterly report
-
Rhea-AI Summary

Turn Therapeutics Inc. reported a third-quarter net loss of $6,230,868, compared with $1,904,184 a year earlier; nine-month net loss was $13,051,733 versus $3,473,150. The quarter included a $3,343,491 net loss from the change in fair value of a derivative liability instrument and $640,122 of amortization of deferred offering and financing costs. Cash and cash equivalents were $10,363,975 at September 30, 2026, compared with $5,076,144 at December 31, 2025.

In a 50-patient Stage 1/Phase 2a atopic dermatitis trial, 59.3% of GX-03 patients achieved clear or almost clear skin after four weeks, versus 30.4% receiving vehicle; 40.7% achieved EASI-100 at Week 8, versus 17.4%. The Phase 2b trial is evaluating 120–136 patients with severe itch, with topline results expected in the first quarter of 2027. Enrollment in an approximately 80-patient hidradenitis suppurativa trial is expected to begin in the first quarter of 2027. Turn Therapeutics expects cash to fund operations into the third quarter of 2027, with additional tranches of capital available from existing facilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.27%
Tags
current report
ARS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
annual report

FAQ

How many Turn Therapeutics (TTRX) SEC filings are available on StockTitan?

StockTitan tracks 54 SEC filings for Turn Therapeutics (TTRX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Turn Therapeutics (TTRX)?

The most recent SEC filing for Turn Therapeutics (TTRX) was filed on November 17, 2026.